Aimmune Therapeutics Inc (AIMT) Shares Sold by Rhumbline Advisers

Share on StockTwits

Rhumbline Advisers lowered its stake in Aimmune Therapeutics Inc (NASDAQ:AIMT) by 6.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 39,031 shares of the biotechnology company’s stock after selling 2,700 shares during the quarter. Rhumbline Advisers owned 0.07% of Aimmune Therapeutics worth $1,065,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Tiverton Asset Management LLC acquired a new stake in Aimmune Therapeutics in the 2nd quarter valued at $145,000. Ardsley Advisory Partners acquired a new stake in Aimmune Therapeutics in the 2nd quarter valued at $202,000. Atria Investments LLC acquired a new stake in Aimmune Therapeutics in the 3rd quarter valued at $213,000. Xact Kapitalforvaltning AB acquired a new stake in Aimmune Therapeutics in the 3rd quarter valued at $221,000. Finally, Metropolitan Life Insurance Co. NY grew its stake in Aimmune Therapeutics by 21.1% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 14,369 shares of the biotechnology company’s stock valued at $386,000 after acquiring an additional 2,501 shares during the period. 75.02% of the stock is currently owned by hedge funds and other institutional investors.

In other Aimmune Therapeutics news, insider Jayson Donald Alexander Dallas bought 3,650 shares of the stock in a transaction on Monday, November 19th. The shares were bought at an average price of $27.56 per share, with a total value of $100,594.00. Following the purchase, the insider now directly owns 63,600 shares in the company, valued at approximately $1,752,816. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 14.70% of the company’s stock.

Shares of AIMT opened at $21.97 on Wednesday. Aimmune Therapeutics Inc has a 52-week low of $21.38 and a 52-week high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.03. Research analysts forecast that Aimmune Therapeutics Inc will post -3.6 earnings per share for the current year.

A number of equities research analysts recently issued reports on the stock. Wedbush set a $80.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 13th. Roth Capital set a $80.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 13th. Credit Suisse Group set a $40.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Wednesday, December 12th. Cantor Fitzgerald set a $64.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 13th. Finally, Goldman Sachs Group assumed coverage on shares of Aimmune Therapeutics in a research note on Thursday, December 13th. They issued a “neutral” rating and a $32.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $49.91.

COPYRIGHT VIOLATION WARNING: This story was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://weekherald.com/2018/12/19/aimmune-therapeutics-inc-aimt-shares-sold-by-rhumbline-advisers.html.

Aimmune Therapeutics Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Read More: Average Daily Trade Volume – What It Means In Stock Trading

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply